Chitosan-Decorated PLGA-NPs Loaded with Tannic Acid/Vitamin E Mitigate Colon Cancer via the NF-κB/β-Cat/EMT Pathway

Nag, Sayoni; Saha, Krishna Das

doi:10.1021/acsomega.1c03477

Cited by 13 publications

(7 citation statements)

References 82 publications

(141 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PLGA NPs initially showed the burst release followed by the sustained release in PBS buffer, whereas in the case of PLGA–CS NPs, the burst phase was shorter, followed by prolonged release kinetics, and, hence, it acted better (Figure ). CS grafting impaired net positive charge over negative charged PLGA NPs that improved mucoadhesive properties and sustained release of drugs as reported by a different research group in their study . In our cellular uptake study, it was confirmed that the composite NPs were easily uptaken by the A549 cell line and that might be due to the improved interaction between cell and composite NPs in comparison to NPs (Figure ).…”

Section: Discussionsupporting

confidence: 83%

“…CS grafting impaired net positive charge over negative charged PLGA NPs that improved mucoadhesive properties and sustained release of drugs as reported by a different research group in their study. 31 In our cellular uptake study, it was confirmed that the composite NPs were easily uptaken by the A549 cell line and that might be due to the improved interaction between cell and composite NPs in comparison to NPs ( Figure 6 ). Hence, it may be assumed that the higher cellular uptake for protein-loaded composite NPs can be achieved by using BSA-loaded PLGA–CS NPs, where these particles also show improved sustained release of BSA.…”

Section: Discussionmentioning

confidence: 52%

See 1 more Smart Citation

Synthesis and Evaluation of BSA-Loaded PLGA–Chitosan Composite Nanoparticles for the Protein-Based Drug Delivery System

et al. 2023

View full text Add to dashboard Cite

The purpose of this study was to synthesize composite nanoparticles (NPs) based on poly(d,l-lactic-co-glycolic acid) (PLGA) and chitosan (CS) and evaluate their suitability for the delivery of protein-based therapeutic molecules. Composite NPs possess a unique property which is not exhibited by any other polymer. Unlike other polymers, only the composite NPs lead to improved transfection efficiency and sustained release of protein. The composite NP were prepared by grafting CS on the surface of PLGA NPs through EDC-NHS coupling reaction. The size of bovine serum albumin (BSA)-loaded PLGA NPs and BSA-loaded PLGA–CS composite NPs was 288 ± 3 and 363 ± 4 nm, respectively. The zeta potential of PLGA NPs is −18 ± 0.23, and that of composite particles is 19 ± 0.40, thus confirming the successful addition of CS on the surface of PLGA NPs. Composite NPs were characterized using dynamic light scattering, scanning/transmission electron microscopy, Fourier transform infrared spectroscopy, X-ray diffraction, release profile, and gel electrophoresis. The encapsulation efficiency of PLGA NPs was 88%. These composite NPs were easily uptaken by the A549 cell line with no or minimal cytotoxicity. The present study emphasizes that the composite NPs are suitable for delivery of BSA into the cells with no cytotoxicity or very little cytotoxicity, while maintaining the integrity of the encapsulated BSA.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Discussionmentioning

confidence: 52%

Synthesis and Evaluation of BSA-Loaded PLGA–Chitosan Composite Nanoparticles for the Protein-Based Drug Delivery System

et al. 2023

View full text Add to dashboard Cite

show abstract

“…A recent study has described the development of polymeric poly D,L‐lactic‐co‐glycolic acid (PLGA) nanostructures for the delivery of tannic acid and vitamin E. The surface modification with chitosan was performed to enhance the stability and biocompatibility of nanostructures. These drug‐loaded PLGA nanoparticles inhibited EMT and invasion of colon cancer cells via inhibiting NF‐κB signaling (Nag & Das Saha, 2021). Overall, it appears that NF‐κB is a vital signaling pathway for promoting metastasis of gastrointestinal cancers via EMT induction.…”

Section: Nf‐κb and Emt Interaction In Various Cancersmentioning

confidence: 99%

NF‐κB as a regulator of cancer metastasis and therapy response: A focus on epithelial–mesenchymal transition

Mirzaei

Saghari

Bassiri

et al. 2022

Journal Cellular Physiology

104

View full text Add to dashboard Cite

Metastasis of tumor cells is a complex challenge and significantly diminishes the overall survival and prognosis of cancer patients. The epithelial‐to‐mesenchymal transition (EMT) is a well‐known mechanism responsible for the invasiveness of tumor cells. A number of molecular pathways can regulate the EMT mechanism in cancer cells and nuclear factor‐kappaB (NF‐κB) is one of them. The nuclear translocation of NF‐κB p65 can induce the transcription of several genes involved in EMT induction. The present review describes NF‐κB and EMT interaction in cancer cells and their association in cancer progression. Due to the oncogenic role NF‐κB signaling, its activation enhances metastasis of tumor cells via EMT induction. This has been confirmed in various cancers including brain, breast, lung and gastric cancers, among others. The ZEB1/2, transforming growth factor‐β, and Slug as inducers of EMT undergo upregulation by NF‐κB to promote metastasis of tumor cells. After EMT induction driven by NF‐κB, a significant decrease occurs in E‐cadherin levels, while N‐cadherin and vimentin levels undergo an increase. The noncoding RNAs can potentially also function as upstream mediators and modulate NF‐κB/EMT axis in cancers. Moreover, NF‐κB/EMT axis is involved in mediating drug resistance in tumor cells. Thus, suppressing NF‐κB/EMT axis can also promote the sensitivity of cancer cells to chemotherapeutic agents.

show abstract

“…CS-coated nanoparticles (NPs) were used to target tumors and increase the anticancer activity. Intraperitoneally injected CS-PLGA-TA-E dramatically reduced tumor number and volume and normalized colon histology in colon cancer patients [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

Baicalin-Loaded Lipid–Polymer Hybrid Nanoparticles Inhibiting the Proliferation of Human Colon Cancer: Pharmacokinetics and In Vivo Evaluation

et al. 2023

View full text Add to dashboard Cite

This research work is focused on pharmacokinetic and biochemical experiments to assess baicalin-loaded lipid–polymer hybrid nanoparticles (LPHNPs) with colon-targeting specificity. The nanoprecipitation method was used to develop the LPHNPs, and the characterized formulation revealed the 184.3 nm particle size, PDI of 0.177, spherical shape, and zeta potential of −19.8 mV. The baicalin LPHNPs are said to be poorly absorbed in the stomach and small intestine, and in vitro drug release tests have shown that the drug is released mostly in the caecal fluid. Additionally, the LPHNPs showed stability and nonsignificant drug loss at 25 °C for 3 months. The least viable population of baicalin-loaded LPHNPs was detected at a lower IC50 value after 48 h, and no cytotoxicity was observed by blank suspension and blank LPHNPs up to the concentration of 100 µg/mL. Apart from this, the pharmacokinetics study showed that baicalin from LPHNPs is much less absorbed and least available in the blood plasma and maximum available in the colon. Concurrently, organ distribution studies demonstrated that baicalin-loaded LPHNPs were distributed more widely in the colon compared to baicalin suspension. Moreover, baicalin-loaded LPHNPs were found to be superior to a baicalin suspension in reducing elevated liver enzyme levels. In a nutshell, baicalin-loaded LPHNPs show superior efficacy and can be maximally localized into the colon rectal cancer along with systemic availability of the drug.

show abstract

Chitosan-Decorated PLGA-NPs Loaded with Tannic Acid/Vitamin E Mitigate Colon Cancer via the NF-κB/β-Cat/EMT Pathway

Cited by 13 publications

References 82 publications

Synthesis and Evaluation of BSA-Loaded PLGA–Chitosan Composite Nanoparticles for the Protein-Based Drug Delivery System

Synthesis and Evaluation of BSA-Loaded PLGA–Chitosan Composite Nanoparticles for the Protein-Based Drug Delivery System

NF‐κB as a regulator of cancer metastasis and therapy response: A focus on epithelial–mesenchymal transition

Baicalin-Loaded Lipid–Polymer Hybrid Nanoparticles Inhibiting the Proliferation of Human Colon Cancer: Pharmacokinetics and In Vivo Evaluation

Contact Info

Product

Resources

About